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Outcome measure Evidence Implications
Disease-oriented evidence
Effective control of serum phosphate and Ca × P product to
within K/DOQI target range
Clear Sevelamer is as effective as calcium salts
Absence of hypercalcemia Clear  Reduced incidence of hypercalcemia with sevelamer compared with
calcium salts
Reduction in serum LDL cholesterol and total cholesterol Clear  Sevelamer is more effective than calcium salts
May have beneficial effects on cardiovascular morbidity and mortality
Reduction in vascular calcification Substantial  Attenuated progression with sevelamer compared with calcium salts
May have beneficial effects on cardiovascular morbidity and mortality
Metabolic acidosis Moderate Sevelamer may be more likely than calcium salts to induce metabolic
acidosis
Preservation of trabecular bone mineral density  Limited Better preservation with sevelamer than with calcium salts
May improve morbidity due to bone disease
Patient-oriented evidence
Improvement in cardiovascular morbidity and mortality Limited Reduced risk of cardiac mortality and morbidity with sevelamer
compared with calcium salts
continued overleaf…
Reduction in serum uric acid concentration Moderate  Greater reduction with sevelamer than with calcium salts
Core evidence place in therapy summary for sevelamer as a phosphate binder in adult
hemodialysis patients
Abstract
Introduction: Patients on hemodialysis require phosphate binders to reduce dietary phosphate absorption and control serum phosphate.
The standard therapy, calcium salts, can be associated with elevated serum calcium (hypercalcemia). Concern has been raised that
hypercalcemia, especially combined with elevated serum phosphate, may be associated with arterial calcification, and this may contribute
to increased risk of cardiovascular mortality and morbidity. Sevelamer is a nonmetal, nonabsorbed phosphate binder. 
Aims: This review assesses the evidence for the therapeutic value of sevelamer as a phosphate binder in adult hemodialysis patients. 
Evidence review: Strong evidence shows that sevelamer is as effective as calcium salts in controlling serum phosphate and
calcium–phosphate product, has less risk of inducing hypercalcemia and is more effective at lowering lipid levels. Some evidence indicates
that sevelamer reduces arterial calcification progression and loss of bone mineral density, but it may be more likely to induce metabolic
acidosis, compared with calcium salts. Sevelamer-containing regimens may improve calcific uremic arteriolopathy, although the evidence
is weak. Evidence is divided on whether the incidence of gastrointestinal adverse events with sevelamer is similar to or higher than that with
calcium salts. Retrospective and modeling studies suggest lower cardiovascular morbidity and mortality with sevelamer than with calcium
salts, with incremental cost-effectiveness of $US1100–2200 per life-year gained. Further direct evidence is needed on mortality, quality of
life, and cost-effectiveness.
Place in therapy: Sevelamer is effective in controlling serum phosphate and lowering lipid levels in hemodialysis patients without inducing
hypercalcemia, and may have beneficial effects on arterial calcification.
Key words: sevelamer, calcium salts, phosphate binder, hemodialysis, chronic kidney disease, evidence
     Scope, aims, and objectives
Sevelamer (Renagel®, Genzyme) is indicated for the treatment of
hyperphosphatemia in adult patients undergoing hemodialysis for
end-stage renal failure. Sevelamer reduces serum phosphate
concentrations by binding phosphate ions in the gastrointestinal
tract, thus preventing systemic absorption. It differs from other
currently available phosphate binders in that it is not a metal salt but
a crosslinked polymer containing multiple amine groups. Sevelamer
is administered in the hydrochloride form with hydrochloride groups
bound to the amine groups. In the gastrointestinal tract, the amine
groups become protonated and positively charged, and preferentially
bind to phosphate ions, displacing some of the hydrochloride.
Maximum phosphate binding occurs at about pH 7, and sevelamer
binds phosphate mainly in the duodenum (Anon. 2004). Studies in
animals and in healthy volunteers have shown that the sevelamer
polymer is not absorbed from the gut, and that both the polymer and
the bound phosphate are excreted in the feces (Burke et al. 1997;
Plone et al. 2002). Sevelamer contains no metal ion component that
could result in potential metal toxicity. The only component of
sevelamer that is absorbed is some of the hydrochloride, which could
contribute to metabolic acidosis (Loghman-Adham 2003). 
This article reviews the evidence for the use of sevelamer as a
phosphate binder in adult patients on hemodialysis, and considers
its effects on outcomes, including serum phosphate and calcium
concentrations, arterial calcification, hospitalization, and
cardiovascular morbidity and mortality. 
Use in children and in patients not undergoing hemodialysis (e.g.
peritoneal dialysis patients or patients not on dialysis) is excluded,
as these indications are not presently approved.
Methods
Literature searches were conducted on January 9–21, 2005, in the
following databases. The search strategy was “Renagel OR
sevelamer” unless otherwise stated. The cut-off date was from the
beginning of the database to the date of the search unless
otherwise stated.
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, 1966 to
date. Search strategy: “sevelamer AND (hemodialysis OR
haemodialysis)” limited to English-language results only, which
was expanded by Automatic Term Mapping to
“(‘sevelamer’[Substance Name] OR sevelamer[Text Word]) AND
((hemodialysis[Text Word] OR haemodialysis[Text Word] OR
(‘renal dialysis’[TIAB] NOT Medline[SB]) OR ‘renal dialysis’[MeSH
Terms]) OR (hemodialysis[Text Word] OR haemodialysis[Text
Word] OR (‘renal dialysis’[TIAB] NOT Medline[SB]) OR ‘renal
dialysis’[MeSH Terms])) AND English[Lang]”
• EMBASE, http://www.datastarweb.com, 1974 to date. Search
strategy: “sevelamer AND (hemodialysis OR haemodialysis)”
limited to English-language results only
• Database of Abstracts of Reviews of Effectiveness (DARE), NHS
Economic Evaluations Database (NHSEED), Health Technology
Assessment (HTA), www.york.ac.uk/inst/crd/darehp.htm. All
three databases were searched together. All fields searched
• NHS HTA, www.ncchta.org
• National Guideline Clearing House, www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
www.nice.org.uk 
• Cochrane Database of Systematic Reviews (CDSR),
www.cochrane.org/index0.htm. Entire site searched
• Clinical Evidence (BMJ), www.clinicalevidence.com
One set of clinical guidelines was identified from the National
Guidelines Clearing House (NKF 2003). After removal of duplicates,
a total of 142 records were retrieved, two from DARE and the
remainder from PubMed or EMBASE. All other databases recorded
no matches. Records were manually reviewed and a total of 114
records were excluded: nonsystematic reviews (n=49), animal
studies (n=3), in vitro studies (n=1), studies in children (n=3), studies
in patients other than hemodialysis patients (n=4), letters, editorials,
comment and corrections (n=25), and articles that mentioned
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Absence of gastrointestinal adverse events Limited Evidence divided on whether the incidence with sevelamer is similar to or
higher than with calcium salts 
Improved patient acceptability (e.g. reduction of the dose
required leading to a lower phosphate binder medication burden)
Limited No improvement over calcium salts
Improvement of ulcers due to calcific uremic arteriolopathy Limited Improvement and/or healing noted after switching to sevelamer in
combination with other interventions
Improvement in quality of life No evidence
Economic evidence
Cost-effectiveness as a phosphate binder in hemodialysis
patients
Limited $US1100–2200 per life-year gained with sevelamer compared with
calcium salts
Cost-effectiveness as a lipid-lowering therapy in predialysis
patients
Limited Less cost-effective than atorvastatin (specific lipid-lowering therapy) plus
calcium salts
…table continued
Outcome measure Evidence Implications
Reduction in hospitalization Limited Lower risk with sevelamer than with calcium salts45
sevelamer but did not investigate its clinical use (n=29). The
remaining 28 records were included in the review. Review of the
reference lists of the systematic review and the meta analysis
identified two further papers for inclusion. An additional study,
submitted to a meeting in 2000 but otherwise apparently
unpublished, was identified in a review article and also included,
bringing the total to 31 (Table 1).
Meeting abstracts from 2002 to date were identified by searching
BIOSIS Previews, http://www.datastarweb.com, 1996 to date,
using the search strategy “sevelamer AND (hemodialysis OR
haemodialysis) AND LG=EN AND PT=MEETING$ AND
(YEAR=2002 OR YEAR=2003 OR YEAR=2004 OR YEAR=2005)” on
February 16, 2005. A total of 21 records were retrieved, of which
nine were excluded because they were animal studies (n=1),
studies that did not investigate the clinical use of sevelamer (n=3),
or duplicate publications of data presented in full papers (n=5). The
remaining 12 were included in the review. In addition, abstracts
from the American Society of Nephrology (ASN) Annual Meeting
2004 were searched on January 20, 2005
(www.abstracts2view.com), using the search terms “(sevelamer OR
Renagel) AND hemodialysis.” This yielded 14 records, of which 10
were excluded because they were animal studies (n=3) or did not
investigate the clinical use of sevelamer in hemodialysis patients
(n=7), leaving four abstracts for inclusion in the review (Table 1). 
The searches were updated on April 29, 2005. After excluding
duplicates, a total of 23 new records were identified, of which 17
were excluded for the following reasons: nonsystematic reviews
(n=6), letters (n=3), and articles that mentioned sevelamer but did
not investigate its clinical use (n=8). Six articles remained, all full
papers, and were included (Table 1). 
For each outcome, preference was given to level 1 and 2 evidence
(see Editorial Information on inside back cover). Level 3 evidence
was also included where level 1 and 2 evidence was lacking or
conflicting. Outcomes from original level 2 or 3 studies, covered in
level 1 evidence, were not considered separately in this review. As
a result, five level 3 papers (Goldberg et al. 1998; Wilkes et al. 1998;
Bleyer et al. 1999; Chertow et al. 1999b; Slatopolsky et al. 1999)
and four level 3 abstracts (Marino et al. 2002; Mitsopoulos et al.
2002a; Sonikian et al. 2002; Yamada et al. 2004) which presented
data only on outcomes for which substantial level 1 and 2 evidence
was identified are not considered in this review. Two level 2 papers
presented only outcomes data that were already included in level 1
evidence and are not discussed separately (Chertow et al. 1997;
Chertow et al. 1999a). 
Disease overview
Chronic kidney disease
Chronic kidney disease (CKD) is classified by the National Kidney
Foundation (NKF) guidelines into five stages of severity, defined
according to the glomerular filtration rate (GFR) (NKF 2003). Stage 5,
kidney failure, is also known as end-stage renal disease (ESRD) or
established renal failure (ERF), and requires renal replacement
therapy (RRT; regular dialysis or a kidney transplant) if the patient is
to survive (NSF 2004). Dialysis must be repeated at regular intervals
for the rest of the patient’s life or until a successful kidney transplant
is performed. The major forms of dialysis are hemodialysis and
peritoneal dialysis, though only hemodialysis is considered in this
review. CKD is a priority area for the UK National Health Service
(NHS), and standards of care are recommended in the National
Service Framework for renal services (NSF 2004). These recommend
that CKD management should begin before dialysis is required, as
this improves outcomes. Treatment should include correction of
anemia, improvement of nutrition, preventing the development of
renal bone disease, management of comorbid diseases (e.g.
cardiovascular disease, diabetes), and helping the patient to choose
and prepare for a particular form of RRT (NSF 2004).
CKD is a common disorder, which is increasing in prevalence as the
average age of populations increases. In England, there were 547
patients per million population undergoing RRT in 2001, up from
396 per million population in 1992 (NSF 2004). In the USA the
number of patients on RRT in 2001 was 1403 per million
population, and in Europe it varied from 606 (Norway) to 1022 per
million population (Catalonia, Spain) (NSF 2004). In England in
2001, patients on RRT were divided approximately equally between
those with a functioning transplant and those on dialysis. However,
the number on hospital hemodialysis is projected to increase faster
than those on other treatments (NSF 2004). 
CKD imposes considerable economic and social burdens on the
patients, their families, and healthcare providers (NSF 2004). It has
been estimated that the treatment of patients undergoing RRT
accounts for 1–2% of the total UK NHS annual budget, while
hemodialysis is estimated to cost approximately £21 000 per
patient per year (NSF 2004). Mortality in CKD patients is higher
compared with the general population; in a survey of 5% of US
Medicare recipients (over 1 million people), the 2-year risk of death
was 17.7 per 100 patient-years for patients with CKD compared
Sevelamer | place in therapy review
Core Evidence 2005;1(1)
Table 1 | Evidence base included in the review
Number of records
Category Full papers Abstracts
Initial search 142 35
records excluded 114 19
records included 28 16
Additional studies identified 3 n/a
Search update, new records 23 0
records excluded 17
records included 6
Total records included 37 16
Level 1 clinical evidence 2 0
Level 2 clinical evidence 11 1
Level ≥3 clinical evidence 22 14
trials other than RCT 20 14
case studies 2 0
Economic evidence 2 1
RCT, randomized controlled trialwith 5.5 per 100 patient-years for those without CKD (Foley et al.
2005). Cardiovascular disease accounts for most of this excess
mortality (McCullough 2004). Patients with CKD have been shown
to have higher risks of congestive heart failure (30.7 vs 8.6 per 100
patient-years) and atherosclerotic vascular disease (35.7 vs 14.1
per 100 patient-years) compared with those without CKD (Foley et
al. 2005).
Hyperphosphatemia in CKD
Hyperphosphatemia is common in patients with stages 4 and 5
CKD. In healthy adults, phosphate absorbed from the diet is
excreted by the kidney, and average daily excretion balances
average daily absorption (Emmett 2004). This is achieved by large
amounts of phosphate being filtered from the blood into the renal
tubule. More than 90% of the filtered phosphate is then
reabsorbed to maintain phosphate balance. Phosphate
reabsorption is regulated by parathyroid hormone (PTH); increased
serum PTH reduces phosphate reabsorption in the kidney tubule
(NKF 2003). In advanced CKD (stage 4 or 5), when the GFR has
fallen to <30 mL/min per 1.73 m2, the kidney can no longer
adequately handle phosphate loads and hyperphosphatemia
develops (NKF 2003).
The average phosphorus intake of adults in North America and
Europe is approximately 1000 mg/day in women and 1500 mg/day
in men, of which about 60–70% is absorbed. A typical 4-h
hemodialysis session removes approximately 1000 mg of
phosphorus (Emmett 2004). However, since hemodialysis is
normally performed every few days, this is not adequate to remove
enough phosphate to restore normal serum phosphate levels
(Hergesell & Ritz 2002).
Phosphate balance is closely connected with calcium balance and
bone metabolism, and numerous interrelated factors influence the
level of serum phosphate in patients with CKD (NKF 2003). Fig. 1
illustrates some of the mechanisms involved.
Normal kidneys produce the active form of vitamin D, which
increases absorption of calcium and phosphate from the gut. In
CKD, levels of active vitamin D drop, producing hypocalcemia,
which in turn stimulates release of PTH. PTH increases bone
resorption and release of calcium and phosphate from the skeleton,
thereby increasing serum calcium and tending to correct the
hypocalcemia. In healthy individuals, PTH also increases urinary
phosphate excretion by decreasing tubular reabsorption. However,
in advanced CKD the kidneys are unable to remove the excess
phosphate and hyperphosphatemia results (NKF 2003). High levels
of serum phosphate are associated with hyperplasia of the
parathyroid glands (Slatopolsky et al. 2001) and directly stimulate
PTH synthesis and secretion (Slatopolsky et al. 2001; NKF 2003),
producing a positive feedback loop in which elevated PTH and
serum phosphate levels increase each other and move the system
further from normal values. Some medical interventions intended to
correct aspects of bone and mineral metabolism in CKD may also
contribute to hyperphosphatemia. For example, administration of
calcitriol (an active form of vitamin D) to patients with CKD may help
to correct hypocalcemia and reduce the excess secretion of PTH,
but may also aggravate hyperphosphatemia by increasing intestinal
absorption of phosphate (NKF 2003). 
Consequences of hyperphosphatemia
Hyperphosphatemia, via its effects on PTH, is established as one of
the causes of osteitis fibrosa in CKD patients (Drüeke 2000; NKF
2003). Osteitis fibrosa is characterized by high serum PTH, high
resorption and high turnover of bone, and may produce skeletal
softening and/or deformation. The high bone turnover releases
skeletal phosphate and calcium and may further increase serum
phosphate levels (see above). The pathogenesis of the other main
form of bone disease in patients with CKD, adynamic bone disease,
is not fully understood, but is thought to be related to
oversuppression of PTH by high calcium intake and/or
administration of calcitriol (NKF 2003). Adynamic bone disease is
characterized by an unusually low turnover of bone and occurs in
15–60% of dialysis patients (NKF 2003). This low bone turnover
means that calcium and phosphate are not absorbed into bone and
accumulate in the blood. Adynamic bone disease can thus
contribute to hyperphosphatemia and hypercalcemia.
In a study of 202 patients followed for a mean of 45 months after
beginning RRT, a serum phosphate level >1.85mmol/L after 1 year
of dialysis was associated with a 2.63 times higher risk of requiring
surgical removal of the parathyroid glands (parathyroidectomy)
than in those with a serum phosphate level ≤1.85 mmol/L
(P=0.006) (Jorna et al. 2004). The association between elevated
serum phosphate and risk of parathyroidectomy was independent
of PTH level, and the authors considered it was likely to be causal
(Jorna et al. 2004).
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Fig. 1 | Pathogenesis of hyperphosphatemia and abnormalities of
mineral and bone metabolism in chronic kidney disease. Ca,
calcium; GFR, glomerular filtration rate; PTH, parathyroid hormone47
Elevated serum phosphate has been shown to be a risk factor for
increased mortality in hemodialysis patients (Block et al. 1998,
2004), and this mortality risk was independent of PTH (Block et al.
1998). A similar risk was observed if the serum
calcium–phosphate product (Ca × P; the calcium concentration in
mg/dL multiplied by the phosphate concentration in mg/dL)
exceeded 72mg2/dL2 (Block et al. 1998). The Dialysis Outcomes
and Practice Patterns Study (DOPPS), conducted in over 6000
dialysis patients from seven countries, also observed that high
serum phosphate and Ca× P were associated with significantly
(P<0.0001) increased cardiovascular and all-cause mortality
(Young et al. 2004). High serum calcium was also associated with
an increased risk of death in two studies (Block et al. 2004; Young
et al. 2004) but not in another (Block et al. 1998). It has been
suggested that serum phosphate may be the major determinant
of Ca × P product (Jorna et al. 2004).
Hyperphosphatemia and elevated Ca × P product are associated
with soft-tissue calcification, in which calcium phosphate
minerals are laid down in soft tissues, such as the blood vessels
(vascular calcification), eyes (ocular calcification), visceral organs
(visceral calcification), skin (cutaneous calcification), and around
the joints (periarticular calcification) (Drüeke 2000; NKF 2003).
Soft-tissue calcification is most common when Ca × P exceeds
70mg2/dL2 (NKF 2003), and is a major mortality and morbidity risk
factor in CKD patients (NKF 2003). It can occur in patients with
elevated PTH and in patients with normal PTH and adynamic
bone disease (Drüeke 2000). 
Soft-tissue calcification in CKD—effects on
morbidity and mortality
The most serious clinical consequences of soft-tissue calcification
are due to visceral or vascular calcification, and may be one
mechanism underlying the excess mortality risk with high serum
phosphate and/or Ca × P observed in hemodialysis patients
(Salusky & Goodman 2000; NKF 2003). It should be noted that
calcium overload can also occur without hypercalcemia, as can the
clinical consequences (e.g. in uremic patients where transfer to the
skeletal buffer is the only route available to “eliminate” excess
ingested calcium). Visceral calcification of the heart muscle, valves,
and/or cardiac conduction system may result in congestive heart
failure, cardiac arrhythmias, and heart block, while calcium
deposition in the lungs may produce pulmonary fibrosis, pulmonary
hypertension, and right ventricular hypertrophy (NKF 2003). 
The prevalence of vascular calcification increases with the length
of time a patient has been on dialysis; prevalence has been
reported as 27% in patients on dialysis for less than 1 year
compared with 83% in those on dialysis for more than 8 years
(NKF 2003). It can involve any artery and shows little tendency to
regress. There are two main forms of vascular calcification (NKF
2003); arteriosclerosis (medial calcification), in which calcium
deposits are laid down in the artery wall stiffening it and reducing
elastic arterial compliance, and atherosclerosis (intimal
calcification), in which calcium deposits are laid down in plaques
on the inner surface of the arterial wall which partially occlude the
lumen and restrict blood flow. Both forms of arterial calcification
have been associated with disturbances of calcium and phosphate
balance (Drüeke & Rostand 2002), and both can cause
cardiovascular complications. Reduction in elastic arterial
compliance increases the strain on the heart and contributes to the
development of left ventricular hypertrophy (Level et al. 2001). In a
cohort of 202 hemodialysis patients, individuals with either intimal
or medial arterial calcification had a significantly (P<0.01) higher
all-cause mortality than patients without calcification (London et
al. 2003). A further study in 110 hemodialysis patients found that
arterial calcification score (assessed by the presence of calcified
plaques detected by ultrasonography and/or calcification visible
on soft-tissue radiographs) and arterial elasticity, were the only risk
factors independently associated with all-cause and
cardiovascular mortality over a mean of 53 months of follow-up
(Blacher et al. 2001).
The causes of arterial calcification are not fully understood. It
appears to be an active process in which vascular smooth muscle
cells actively take up phosphate and begin to express osteoblast
markers (osteoblasts are bone-forming cells) (Floege & Ketteler
2004). Endogenous regulators of calcification, such as fetuin A,
osteoprotegerin and matrix Gla protein, may be associated with the
pathogenesis of vascular calcification, but their precise role
remains to be clarified (Kazama 2004; Floege & Ketteler 2004).
Some authorities consider that high doses of calcium salts used as
phosphate binders may play an important role, via intestinal
absorption of calcium and elevated serum Ca × P product (Salusky
& Goodman 2000; Drüeke 2001). In support of this, a study in 120
hemodialysis patients found that, after adjustment for confounding
factors, the prescribed dose of calcium carbonate was one of four
variables independently associated with arterial calcification
(measured by ultrasonography) (Guérin et al. 2000). A further small
study in 24 hemodialysis patients found that impaired arterial
compliance was associated with duration of hemodialysis and
serum total calcium (Level et al. 2001).
Others have argued that dyslipidemia is an important determinant
of vascular calcification (McCullough et al. 2004; Qunibi et al.
2004). A systematic review of 30 studies of coronary vascular
calcification in patients with CKD found that the most consistent
determinants of calcification were increasing age and duration of
dialysis (McCullough et al. 2004). Measures of calcium–phosphate
balance were found to be associated with calcification in eight
studies, while 20 studies found no association (McCullough et al.
2004). The authors also reported that serum lipid profile was
associated with vascular calcification in four studies, and
concluded that dyslipidemia was possibly associated with vascular
calcification, whereas calcium–phosphate balance showed
inconsistent results and was “likely not related” (McCullough et al.
2004). However, it seems that results linking lipid profile to vascular
calcification may also be inconsistent, since the authors identified
two further studies that found no association between vascular
calcification and lipid profile (McCullough et al. 2004). In a study of
453 mainly African-American patients on hemodialysis, it was
found that 2-year mortality did not correlate with hyperlipidemia
(Fleischmann et al. 2001).
There is evidence that the two forms of arterial calcification may
differ in their epidemiology. In a cohort of 202 hemodialysis
patients, intimal calcification was observed mainly in older patients
with typical atherosclerotic risk factors, including dyslipidemia,
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patients and was associated with CKD-specific factors, including
longer duration of hemodialysis and high serum phosphate
(London et al. 2003). Such differences in epidemiology between the
two forms may explain the apparent inconsistency of reported
associations between vascular calcification and risk factors, but
further research is required to clarify this.
A small number of patients with vascular calcification and
advanced CKD develop progressive skin ulcerations and tissue
necrosis, a syndrome called calciphylaxis or calcific uremic
arteriolopathy (Llach 2001; NKF 2003). The mechanism is not well
understood, although hyperphosphatemia is an important factor
(NKF 2003), and calcium toxicity may also be involved (Llach 2001).
The prognosis of patients with calcific uremic arteriolopathy is poor,
with most dying of sepsis or ischemic events (Llach 2001). 
Metabolic acidosis in CKD
Blood pH, partial pressure of carbon dioxide (CO2), and serum
bicarbonate concentration are chemically related to one another by
a fixed equation, and the key determinant of blood pH is the ratio
of dissolved CO2 to bicarbonate in the serum. In healthy individuals,
the lungs adjust the partial pressure of CO2 (which determines the
concentration of dissolved CO2) and the kidneys adjust the
concentration of bicarbonate. A fall in blood pH resulting from an
increase in CO2 is termed respiratory acidosis, while a fall in blood
pH resulting from a fall in serum bicarbonate is termed metabolic
acidosis. 
Metabolic acidosis in patients with kidney failure may be linked to
malnutrition and inflammation (Kalantar-Zadeh et al. 2004), and it
has been suggested that acidosis could be associated with an
increased risk of death and increased dissolution of bone (Brezina
et al. 2004). The NKF Kidney Disease Outcomes Quality Initiative
(K/DOQI) guidelines recommend that predialysis serum levels of
total CO2 should be maintained at ≥22 mmol/L (NKF 2003). Total
CO2 is readily measured by automated analyzers and is considered
an appropriate proxy for serum bicarbonate (Bommer et al. 2004).
However, the NKF K/DOQI guidelines consider that acidosis does
not play an important role in the pathogenesis of bone disease in
CKD (NKF 2003). Furthermore, results from the DOPPS study found
that patients with moderate acidosis (predialysis serum total CO2
levels of 20.1–22 mmol/L) had lower mortality and hospitalization
risks than patients with either severe acidosis (predialysis serum
total CO2 levels of ≤17 mmol/L) or high predialysis serum total CO2
level (>27 mmol/L) (Bommer et al. 2004). There is a lack of evidence
for reducing acidosis with bicarbonate supplementation, and its
true clinical impact on calcification is unclear.  
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Drug class Compound Phosphate-binding effects Disadvantages
% of dietary
phosphorus absorbeda
Phosphorus
binding/gram of drug
Aluminum salts Aluminum hydroxide,
aluminum carbonate
Normal subjects: 18% 
Dialysis patients:
35–49%
Not available Large doses required 
Unpleasant taste
Can cause constipation
Aluminum accumulation and toxicity to skeleton, central
and peripheral nervous system, parathyroid glands, and
hematopoietic cells
Calcium salts Calcium carbonate Normal subjects: 44% 4.65–17 mg Large doses required (8–10 g/day)
Poor phosphate binding at neutral pH
Hypercalcemia reported in one-third of patients
Calcium acetate Normal subjects: 26% 6.76–27 mgb Large doses required (6–8 g/day)c
Gastrointestinal effects can occur
May be associated with hypercalcemia
Lanthanum salts Lanthanum carbonate Not available Not available Moderate doses required (1.5–3 g/day)d
Gastrointestinal adverse events can occurd
Small amounts of lanthanum are absorbed and there is a
possibility of accumulation with chronic use; long-term
safety data are needed to assess this
aWithout phosphate binders, 66–77% of dietary phosphate is absorbed (Emmett 2004).
bOriginal reference (Loghman-Adham 2003) gives the lower end of the range as 46.76, but this does not agree with the mmol value given in the same source, which is 0.218. However, a value of
6.76 mg for the lower end of the range does match the mmol value.
cSource: PhosLo® US package insert.
dSource: Fosrenol® prescribing information (available at: http://www.fosrenol.com/prescribingInfo.pdf).
Nonaluminum,
noncalcium phosphate
binders
Sevelamer Not available 77.5–84 mg Large doses required (5–7 g/day)
Gastrointestinal effects at high doses, similar frequency to
high-dose calcium salts
Absorption of released hydrochloride may contribute to
metabolic acidosis
Table 2 | Main currently available phosphate binders (adapted from Loghman-Adham 2003; Emmett 2004)
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Current therapy options
There are three components to a strategy for controlling serum
phosphate in ESRD: phosphate removal by dialysis, dietary restriction
of phosphate, and use of oral phosphate binders (Emmett 2004). The
effect of dietary restriction and dialysis is limited because phosphate
is abundant in all food groups, and maintaining an adequate protein
intake will also result in a phosphate intake that exceeds the amount
that can be removed by most forms of dialysis (Loghman-Adham
2003; Emmett 2004). However, there is some recent evidence that
quotidian (i.e. short daily dialysis) is more effective than conventional
hemodialysis in reducing serum phosphate and the need for
phosphate binders (Achinger & Ayus 2005). 
Oral phosphate binders are normally required for most patients
(Emmett 2004). The main currently available phosphate binders are
listed in Table 2. Other compounds are used occasionally or are in
development (e.g. magnesium salts and iron preparations)
(Hergesell & Ritz 2002; Loghman-Adham 2003; Emmett 2004).
The occurrence of progressive and sometimes fatal aluminum
intoxication in some patients taking aluminum salts has been
described as a “medical catastrophe” (Hergesell & Ritz 2002), and
calcium salts have become the most widely used class of
phosphate binder (Salusky & Goodman 2000). Table 3 shows the
usage of phosphate binders reported in various surveys.
Lanthanum carbonate has only recently been approved (October
2004 in the USA) and did not feature in the surveys.
Unmet needs
Significant problems remain with calcium salts. Large doses are
required, especially with calcium carbonate. Calcium carbonate
binds phosphate poorly at neutral pH and may have lower
effectiveness in patients with impaired gastric acid secretion
(Loghman-Adham 2003). Calcium acetate has about twice the
phosphate-binding capacity of calcium carbonate, expressed
per milligram of elemental calcium, and can be given at a
somewhat lower dose. However, it can cause gastrointestinal
adverse effects (Loghman-Adham 2003). As discussed in the
previous section, calcium salts have been associated with an
increased incidence of arterial calcification, which has been
associated with elevated cardiovascular mortality, although the
nature of the relationship is not known (Emmett 2004). The lower
dose of elemental calcium required with calcium acetate
compared with calcium carbonate should theoretically reduce
the amount of calcium absorbed and hence the risk of
hypercalcemia, but a subanalysis of a randomized controlled trial
(RCT) found that changes in arterial calcification (as measured by
electron beam tomography) in patients receiving calcium acetate
were similar to those in patients receiving calcium carbonate
(Chertow et al. 2003). 
Lanthanum carbonate has only recently become available (FDA
approval October 2004). It has the potential to reduce the dosage
somewhat compared with calcium salts; median dose required for
phosphate control reported as 2.25 g/day for lanthanum carbonate
compared with 3 g/day for calcium carbonate (Loghman-Adham
2003). However, small amounts of lanthanum are absorbed and
concerns remain that chronic exposure may lead to lanthanum
accumulation and potential toxicity (Hergesell & Ritz 2002; Emmett
2004). Long-term safety data are needed to address these
concerns (Hergesell & Ritz 2002; Loghman-Adham 2003).
Compliance with treatment guidelines
The NKF K/DOQI treatment guidelines set out targets for various
components of calcium–phosphate balance (Table 4).
Several surveys have shown that few patients successfully attain
these targets. In a survey of 188 dialysis patients in the USA, only
11 (5.9%) were within the recommended ranges for all five
parameters (Tomasello et al. 2004). In another survey among 1312
patients on hemodialysis at seven centers in Spain, only 13% met
K/DOQI targets for Ca × P, serum phosphate, and PTH (Lorenzo et
al. 2004). While more than half the patients surveyed in the DOPPS
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Lorenzo et al.
2004
Manley et al.
2004 (DCI)
Manley et al.
2004 (USRDS)
Patient
population
1312 HD
patients from 7
centers in Spain
10 474 HD
patients treated
at DCI units in
the US
Data on a
sample of 1998
HD patients from
the USRDS
Phosphate
binder used
(% of patients)
Any phosphate
binder
71% 88% 80%
Calcium acetate NRa 43.4% 35%
Calcium
carbonate
NRa 24% 35%
Any calcium salt 51% NR NR
Sevelamer 21% 31.1% NR
Aluminum 16% 2.8% 6.1–10%
aOriginal source did not distinguish between individual calcium salts. 
DCI, Dialysis Centre Inc; HD, hemodialysis; NR, not reported; USRDS, United States Renal
Data System.
Table 3 | Phosphate binder usage (values may not sum as
patients may have been taking more than one agent.
The USRDS data were collected prior to 1996 and
pre-date the introduction of sevelamer)
Parameter Target
Serum phosphate (mg/dL) 3.5–5.5
Serum calcium (mg/dL) 8.4–9.5
Serum Ca × P (mg2/dL2) <55
Serum intact PTH (pmol/L) 150–300
Elemental calcium intake from phosphate binders
(mg/day)
≤1500
Ca × P, calcium–phosphate product; PTH, parathyroid hormone.
Table 4 | NKF K/DOQI targets for parameters of
calcium–phosphate balance in patients with CKD
stage 5 (adapted from NKF 2003)
 study were outside the target ranges for serum calcium, serum
phosphate, and PTH across all seven countries, there was a trend
towards improvement between the first DOPPS survey in
1996–2001 and the second in 2002–2004 (Young et al. 2004). In a
small survey in 69 hemodialysis patients at a single center in the
Czech Republic (not included in DOPPS), only 20% of patients met
all the targets (Smrzova et al. 2004). The low level of compliance
with the NKF K/DOQI guidelines thus indicates that substantial
unmet needs still remain in the control of hyperphosphatemia in
hemodialysis patients.
One problem is that patient adherence to phosphate binder therapy
is poor (Hergesell & Ritz 2002); in a survey of 188 US dialysis
patients, 37.8% of patients admitted noncompliance (compliance
defined as at least 80% of phosphate binders taken correctly)
(Tomasello et al. 2004). The main reasons given for noncompliance
were being unaware of the correct prescription (37% of
noncompliant patients) and forgetting the dose (30%). However, the
burdensome nature of the large doses was also mentioned by
some patients: 6% said there were too many pills, 8% said they
missed a dose because they were eating out, and 4% said the
binder doses were too big to carry (Tomasello et al. 2004).
Although current phosphate binders may be effective, they have
limitations and adverse effects that may compromise optimal
treatment. Alternative agents with improved therapeutic value
should retain or improve on the effectiveness of current treatments
while avoiding or reducing their limitations. The attributes of an
ideal phosphate binder include effective control of serum
phosphate and Ca × P product to within K/DOQI target range;
avoidance of hypercalcemia; absence of metal absorption that may
lead to toxicity; absence of troublesome adverse events; improved
patient acceptability (e.g. reduction of the dose required leading to
a lower tablet burden) and/or improved patient adherence; wide
dose range and flexible dosing to accommodate individual
differences in dietary phosphate intake; reduction in the risk of soft-
tissue and especially vascular calcification; improvement in the
morbidity due to bone disease; improvement in cardiovascular
morbidity and mortality; improvement in quality of life; and
demonstrated cost-effectiveness. 
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Level of
evidence
Design Treatment and
mean dose
Outcome Reference
Serum
phosphate
Serum Ca Incidence of
hypercalcemia
(≥11 mg/dL or
>2.8 mmol/L)a
Serum Ca × × P Serum PTH
1 Meta analysis  Sevelamer Mean decrease
2.14 mg/dL vs
baseline
(P<0.001)
(11 studies)
Mean increase
0.09 mg/dL vs
baseline (NS)
(9 studies)
NR Mean decrease
15.9 mg2/dL2 vs
baseline
(P<0.001)
(9 studies)
Mean decrease
35.99 pg/mL vs
baseline
(P=0.026)
(3 studies)
Burke et al.
2003
1 Systematic
review
Sevelamer
Sevelamer plus
supplemental
Ca
Placebo
CaAc
CaCO3
Lower with S vs
placebo (P<0.04)
(1 study)
NSD S vs Ca
salts (4 studies)
NSD S vs S+Ca
(1 study)
NSD S vs placebo
(1 study)
NSD S vs CaCO3
(1 study)
NSD S vs S+Ca
(1 study)
Smaller increase with
S vs Ca salts (P<0.01)
(3 studies)
Lower with S vs
CaAc or CaCO3
(P<0.0001)
(2 studies)
NSD S vs Ca
salts (3 studies)
NSD S vs S+Ca
(1 study)
NSD S vs Ca
salts (4 studies)
NSD S vs S+Ca
(1 study)
Manns et al.
2004
2 Open, RCT, 34
weeks, n=40 in
total
Sevelamer
4.09 g/day
CaAc 3.9 g/day
Similar decrease
for S and CaAcb
NSD vs baseline for S
and CaAcb
NSD S vs CaAc  Similar decrease
for S and CaAcb
Similar decrease
for S and CaAcb
Hervás et al.
2003
2 Open, RCT, 52
weeks, n=36
(S), n=46
(CaCO3)c
Sevelamer
5.9 g/day
CaCO3
3.9 g/day
NSD S vs
CaCO3
Smaller increase with
S vs CaCO3 (P<0.01)
Lower with S vs
CaCO3 (P<0.01)
NSD S vs
CaCO3
Decrease for
CaCO3 vs
baseline
(P<0.01); NSD
vs baseline for
Sb
Braun et al.
2004
2 Double-blind,
RCT, 8 weeks,
n=50 (S), n=48
(CaAc)
Sevelamer
6.9 g/day
CaAc 7.1 g/day
Higher with S vs
CaAc
(P=0.0006)
Lower with S vs CaAc
(P<0.0001)
Lower with S vs
CaAc
(P<0.0001)
Higher with S vs
CaAc (P=0.022)
NSD S vs CaAc Qunibi et al.
2004
aDefinition varied between studies; 2.8 mmol/L = 11.2 mg/dL.
bNo between-group statistical comparison reported.
cNinety-three of the 114 patients randomized were included in the primary publication of the Treat To Goal study (Chertow et al. 2002), which was one of the studies included in Manns et al. (2004).
CaAc, calcium acetate; CaCO3, calcium carbonate; NR, not reported; NS, not statistically significant; NSD, no statistically significant difference; RCT, randomized controlled trial; S, sevelamer.
Table 5 | Effects of sevelamer on serum phosphate, calcium (Ca), calcium–phosphate product (Ca × P), parathyroid hormone (PTH),
and incidence of hypercalcemia
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Clinical evidence with sevelamer
Numerous outcomes have been measured in the published
evidence. The majority of the evidence related to disease-oriented
outcomes, such as effects on serum phosphate, serum calcium,
dyslipidemia, serum uric acid, metabolic acidosis, arterial
calcification and bone mineral density. Patient-oriented outcomes
included cardiovascular morbidity and mortality, improvement of
calcific uremic arteriolopathy, and risk of hospitalization, but the
evidence base for these outcomes was smaller.
Serum phosphate
The evidence demonstrates that sevelamer is effective in
reducing serum phosphate from pretreatment (baseline) values.
Most of the evidence (all five studies in the systematic review, and
two of three further RCTs) shows that sevelamer is as effective as
calcium salts in reducing serum phosphate, and that sevelamer
alone is as effective as sevelamer plus supplemental calcium
(Table 5). However, one RCT (Qunibi et al. 2004) reported that
serum phosphate was significantly higher with sevelamer than
with calcium acetate (Table 5), although at 8 weeks’ duration this
study was shorter than most of the other trials [six of the seven
studies reviewed by Manns et al. (2004) were >8 weeks].
Furthermore, this study used a formulation of sevelamer (403 mg
capsules) that is no longer available, and did not use a dose of
sevelamer that was equipotent to the dose of calcium acetate.
The Qunibi et al. (2004) study used a double-blind design,
whereas the other comparisons between sevelamer and calcium
salts were open label and thus could be considered weaker.
However, blinding should have had little, if any, effect on objective
measurements of absolute values such as serum phosphate.
Qunibi et al. (2004) also used a different measure of serum
phosphate, time-averaged serum phosphate over 1–8 weeks as
opposed to mean change from baseline to end of treatment,
compared with the other studies, and it is possible that this may
account for the different results. 
Serum calcium
Burke et al. (2003) found in their meta analysis that sevelamer had
a small and statistically insignificant effect on serum calcium (see
Table 5). The results of the review by Manns et al. (2004) are
consistent with this, as the four RCTs comparing sevelamer with
calcium salts showed only small mean changes in serum calcium,
ranging from an increase of 0.2 mg/dL to a decrease of
0.05 mg/dL with sevelamer (Manns et al. 2004). This wide range
may be due in part to variations in the dialysate calcium
concentration utilized in the studies.  In all four studies the mean
increase with sevelamer was lower than with the calcium salt; the
difference was statistically significant in three studies (P<0.01)
and not statistically significant in one study (Manns et al. 2004).
There was no statistically significant difference between
sevelamer alone and sevelamer with supplemental calcium (see
Table 5).
On balance, the current evidence shows that sevelamer has little
effect on serum calcium levels, and is less prone to increase serum
calcium levels than calcium salts, although none of these trials was
powered to detect a difference.
Incidence of hypercalcemia
There is strong evidence that sevelamer is associated with a
statistically significantly (P<0.01) lower incidence of hypercalcemia
than calcium salts (both the trials in the systematic review that
reported data on this outcome, and two of three further trials) (see
Table 5). Although one RCT reported no statistically significant
difference between sevelamer and calcium acetate, it was not
powered to detect a difference (Hervás et al. 2003).
Serum Ca × × P product
Most of the evidence demonstrates that sevelamer is as effective as
calcium salts in decreasing serum Ca × P (see Table 5). One
exception, the RCT of Qunibi et al. (2004), reported that calcium
acetate decreased Ca ×P significantly more than sevelamer. However,
as discussed in the section on serum phosphate, this study was of
short duration compared with the others and used time-averaged
concentrations rather than change from baseline to endpoint.
Parathyroid hormone 
Evidence from the meta analysis, systematic review, and two of
three further RCTs shows that sevelamer was as effective as
calcium salts in reducing serum PTH, and that addition of
supplemental calcium did not produce a statistically significant
difference (see Table 5). 
Intact PTH, the form measured in the studies in Table 5, consists
of 84 amino acids (1-84 PTH). The N-terminally-truncated
molecule (7-84 PTH) may have different effects from the intact
molecule, being associated with hypocalcemia and decreased
bone turnover (rather than hypercalcemia and increased bone
turnover). In a small study of 17 hemodialysis patients, sevelamer
treatment for 5 weeks significantly (P=0.03) reduced serum 1-84
PTH, but had no statistically significant effect on 7-84 PTH
(Chudek et al. 2003). The clinical significance of effects on different
forms of PTH remains unresolved. 
Vascular calcification
There is evidence from the RCT conducted by the Treat to Goal
Working Group (Chertow et al. 2002) that sevelamer is associated
with significantly greater reductions in calcification scores (using
electron beam tomography) than calcium salts after 52 weeks of
treatment (Table 6). Subanalyses of the primary study (Chertow et
al. 2003; Braun et al. 2004) found that this remained true when
sevelamer was compared with either calcium acetate (US patients;
Chertow et al. 2003) or calcium carbonate (German and Austrian
patients; Braun et al. 2004) (see Table 6). The benefit in reduced
calcification was greatest in patients with poorly controlled
phosphate and Ca × P product (Braun et al. 2004). A further
analysis (Raggi et al. 2004) reported that mitral and aortic valve
calcification scores were not significantly different between the
treatment groups, but that significantly more sevelamer patients
experienced a regression in total calcification burden (derived by
combining vascular and valve calcification scores) compared with
calcium-treated patients (see Table 6).
A further subanalysis presented data from 150 patients in the Treat
to Goal study who had electron beam tomography data at baseline
and after either 26 or 52 weeks of treatment with sevelamer or
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                                    calcium salts (Chertow et al. 2004). In patients treated with calcium
salts, the change in coronary calcification was significantly
correlated with serum phosphorus (r=0.22, P=0.04) and Ca × P
product (r=0.26, P=0.02), and the change in aortic calcification was
significantly correlated with serum calcium (r=0.28, P=0.01). None
of the corresponding correlations were statistically significant in the
sevelamer group (Chertow et al. 2004).
As discussed in the Disease overview section above, medial
calcification is associated with arterial stiffening. A separate study
in Japan measured the change in pulse wave velocity in 15
patients during the 6 months before they were switched from
calcium carbonate to sevelamer and during the 6 months after the
switch (level 3 evidence; Takenaka & Suzuki 2005). Increased
pulse wave velocity indicates increased arterial stiffness (London
et al. 2004). In the 6 months before the switch, mean pulse wave
velocity increased by 46 cm/s per month, while in the 6 months
after switching to sevelamer pulse wave velocity decreased by
20 cm/s per month (P<0.01 for comparison between the two
periods). These findings indicate that calcium carbonate
treatment was associated with a progressive increase in pulse
wave velocity, which was reversed by sevelamer treatment
(Takenaka & Suzuki 2005).
Calcific uremic arteriolopathy
An observational study reported data from eight patients with
calcific uremic arteriolopathy (calciphylaxis) who were managed
with zero-calcium dialysate and switched from calcium-based
phosphate binders to sevelamer (Llach 2001). Six of the eight
patients showed “dramatic improvement” (no criteria specified) in
their skin lesions, according to the author, and four showed total
healing (Llach 2001). 
Case reports of three patients have described similar results.
Russell et al. (2002) described a 73-year-old man with calcific
uremic arteriolopathy and leg ulcerations, whose lesions healed
after switching from calcium-based phosphate binders to
sevelamer, discontinuing vitamin D analogs and receiving
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Design Treatment and
mean dose
Outcome Reference
Mean change
in coronary
artery
calcification
score vs
baseline at 52
weeks
Mean change
in aorta
calcification
score vs
baseline at 52
weeks
Mean change
in mitral valve
calcification
score vs
baseline at 52
weeks
Mean change
in aortic valve
calcification
score vs
baseline at 52
weeks
Patients with
no progression
of total
calcification
burden
Patients with
regression of
total
calcification
burden
Open, 52
weeks, n=62
(S), n=70 (Ca
salts)a
Calcification
score assessor
blinded to study
treatment
Sevelamer
6.5 g/day
Ca salts
4.3 g/day
S decrease 46 
Ca salts
increase 151
(P<0.04 S vs Ca
salts) 
S decrease 532 
Ca salts
increase 185 
(P=0.01 S vs Ca
salts) 
NR NR NR NR Chertow et al.
2002
Subanalysis of
Chertow et al.
2002, US
patients only,
n=108
randomized
Sevelamer
6.7 g/day
CaAc
4.6 g/day
S increase 64
(NS vs baseline)
CaAc increase
182 (P=0.002 vs
baseline)
S decrease 127
(NS vs baseline)
CaAc increase
181 (P<0.0001
vs baseline)
NR NR NR NR Chertow et al.
2003
Subanalysis of
Chertow et al.
2002, German
and Austrian
patients, with 11
additional
patients
randomized,
n=36 (S), n=46
(CaCO3)a
Sevelamer
5.9 g/day
CaCO3
3.9 g/day
S decrease 130
CaCO3 increase
200
(P=0.02 S vs
CaCO3)
S decrease 897 
CaCO3 increase
240
(P<0.01 S vs
CaCO3)
NSD vs baseline
for S and
CaCO3
NSD vs baseline
for S and
CaCO3
NR NR Braun et al.
2004
Re-analysis of
Chertow et al.
2002, to include
data on heart
valve
calcification
Sevelamer
6.5 g/day
Ca salts
4.3 g/day
NR NR S decrease 655 
Ca salts
increase 98
(NS S vs Ca
salts)
S increase 24
Ca salts
increase 24
(NS S vs Ca
salts)
S 45%
Ca salts 28%
(P=0.047 S vs
Ca salts)
S 26%
Ca salts 10%
(P=0.02 S vs Ca
salts)
Raggi et al.
2004
aPatients with data at 52 weeks.
Ca, calcium; CaAc, calcium acetate; CaCO3, calcium carbonate; NR, not reported; NS, not statistically significant; NSD, no statistically significant difference; S, sevelamer.
Table 6 | Effects of sevelamer compared with calcium salts on vascular calcification (all level 2 evidence)
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aggressive wound care. The healing was paralleled by a decrease
in serum phosphate and Ca × P product (Russell et al. 2002). Don
and Chin (2003) described two women with calcific uremic
arteriolopathy whose lesions healed after switching from calcium-
based phosphate binders to sevelamer and undergoing more
frequent hemodialysis with a low-calcium dialysate. This treatment
also resulted in a reduction in serum phosphate and Ca × P product
(Don & Chin 2003).
These case reports and case series indicate that using sevelamer
as part of a treatment regimen to reduce Ca × P product may have
a beneficial effect in patients with calcific uremic arteriolopathy.
However, it should be noted that other calcium-sparing phosphate
binders may be equally effective, and no evidence has compared
sevelamer with alternative noncalcium phosphate binding
compounds in calcific uremic arteriolopathy.
Serum lipids
Strong evidence shows that sevelamer significantly reduces low-
density lipoprotein cholesterol (LDL cholesterol) and total
cholesterol, and that it is significantly more effective on these
outcomes than calcium salts (Table 7).
Serum uric acid
Elevated serum uric acid concentrations are common in patients with
advanced CKD and are associated with the development of gout,
although clinically it is relatively insignificant. Nevertheless, evidence
indicates that sevelamer treatment is associated with a statistically
significant reduction in mean serum uric acid concentration
compared with baseline, and in one RCT (Garg et al. 2005) the
reduction observed with sevelamer was greater than that observed
with calcium salts (Table 8).
Metabolic acidosis
Since some of the hydrochloride component of sevelamer is
absorbed, this may theoretically promote the development of
acidosis, in contrast to the calcium-based phosphate binders.
Absorption of hydrochloride increases the amount of H+ ions
absorbed (acid load); the H+ ions react with bicarbonate ions in the
serum to form CO2 and water, reducing the serum bicarbonate
concentration. If the excess CO2 can be removed by the lungs
(respiratory compensation), the ratio between CO2 and bicarbonate
(and hence blood pH) may be maintained within the normal range,
although at lower absolute levels of CO2 and bicarbonate.
Evidence is divided on whether sevelamer lowers serum bicarbonate
more than calcium salts (Table 9). Of the studies reported in the
systematic review, one showed no difference from placebo, one
showed no difference between sevelamer with and without
supplemental calcium, one showed no difference from calcium salts,
and one showed lower serum bicarbonate with sevelamer compared
with calcium salts (19.2 mmol/L vs 22.1 mmol/L, P<0.0001). A further
RCT reported that after 8 weeks of treatment, mean serum
bicarbonate was significantly lower with sevelamer than with calcium
acetate (19.3 mmol/L vs 21 mmol/L, P<0.0001). A retrospective study
in 17 patients treated with sevelamer for 2 years found that mean
serum bicarbonate declined significantly during treatment (from
20 mEq/L to 17.9 mEq/L, P=0.002), while there was no statistically
significant change in serum bicarbonate in seven control patients who
received calcium- or aluminum-based phosphate binders for the
same length of time (Sonikian et al. 2005). This study also reported
significant increases in serum potassium (from 5.45 mEq/L to
5.75 mEq/L,  P=0.02) and mean intact parathyroid hormone (from
132.8 pg/mL to 326.9 pg/mL, P=0.0008) in the sevelamer-treated
patients, with no statistically significant change in the controls, and
the authors suggest that secondary hyperparathyroidism and
elevated serum potassium could be related to metabolic acidosis.
However, they also reported that correlations between serum
bicarbonate changes and sevelamer dose, and between serum
bicarbonate and intact parathyroid hormone, were not significant
(Sonikian et al. 2005). Two retrospective studies presented in abstract
form reported that a higher proportion of sevelamer-treated patients
had serum bicarbonate <20 mmol/L compared with patients receiving
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Level of
evidence
Design Treatment and
mean dose
Outcome Reference
LDL cholesterol Total cholesterol
1 Meta analysis
(10 studies)
Sevelamer Mean decrease 31.38 mg/dL vs baseline
(P<0.001) 
Mean decrease 30.58 mg/dL vs baseline
(P<0.001) 
Burke et al.
2003
1 Systematic
review
Sevelamer
Placebo
CaAc
CaCO3
Lower with S vs placebo (1 study)
Lower with S vs Ca salts (3 studies)
Lower with S vs placebo (1 study)
Lower with S vs Ca salts (2 studies)
Manns et al.
2004
2 Open, RCT, 34
weeks, n=40 in
total
Sevelamer
4.09 g/day
CaAc 3.9 g/day
Decrease vs baseline for S (P<0.05); NSD vs
baseline for CaAc
Decrease vs baseline for S (P<0.05); NSD vs
baseline for CaAc
Hervás et al.
2003
2 Open, RCT, 52
weeks, n=36
(S), n=46
(CaCO3)a
Sevelamer
5.9 g/day
CaCO3
3.9 g/day
Decrease vs baseline for S (P<0.01); NSD vs
baseline for CaCO3
Decrease vs baseline for S (P<0.01); NSD vs
baseline for CaCO3
Braun et al.
2004
aNinety-three of the 114 patients randomized were included in the primary publication of the Treat To Goal study (Chertow et al. 2002), which was one of the studies included in Manns et al. (2004).
Ca, calcium; CaAc, calcium acetate; CaCO3, calcium carbonate; NSD, no statistically significant difference; RCT, randomized controlled trial; S, sevelamer.
Table 7 | Effects of sevelamer on serum low-density lipoprotein (LDL) cholesterol and total cholesterol
                                            calcium salts (see Table 9), although since these studies were not
randomized they may have been subject to selection bias. 
A nonrandomized study reported in abstract form (Vlahakos et al.
2004) found that 2 years of treatment with sevelamer produced a
reduction in the mean partial pressure of CO2 and a slight reduction in
serum pH, though serum pH remained within the normal range (see
Table 9). This pattern is consistent with chronic metabolic acidosis in
the sevelamer group (reflecting the increased acid load from the
hydrochloride component), with respiratory compensation reducing
the partial pressure of CO2 to maintain serum pH in the normal range. 
Thus, it seems that sevelamer can produce modest reductions in
serum bicarbonate, but does not consistently do so. It is not clear
whether such reductions are of clinical significance; the K/DOQI
guidelines recommend that serum total CO2 should not fall below
22 mmol/L (NKF 2003), but results from the DOPPS study found
that a moderate acidosis (predialysis serum total CO2 levels of
20.1–22 mmol/L) was associated with a reduction in hospitalization
and mortality risk (Bommer et al. 2004). As mentioned earlier, there
is a lack of evidence on the clinical significance of acidosis, the
impact of bicarbonate supplementation, and what constitutes an
appropriate endpoint.
Gastrointestinal tolerability 
Gastrointestinal adverse events were not consistently defined and
reported in the published studies. In the studies that provided some
evidence on the occurrence of gastrointestinal adverse events for
sevelamer compared with calcium salts the evidence was
conflicting, with two studies reporting a higher incidence of
gastrointestinal adverse events for sevelamer and four reporting no
difference (Table 10). 
In a single-group study in 19 hemodialysis patients in Italy switched
from calcium carbonate (with or without additional aluminum salts)
to sevelamer, two patients withdrew because of gastrointestinal
adverse events (one for diarrhea, one for nausea and heartburn),
and a further patient reported dyspepsia as an adverse event
(Gallieni et al. 2001). A second single-group study in 27
hemodialysis patients in France reported that sevelamer treatment
was associated with “minor but poorly tolerated adverse events”
including constipation (32%), vague abdominal pain (27%),
diarrhea (23%), and gastric dyspepsia (18%) (Huu et al. 2002). The
authors noted that the incidence of adverse events progressively
diminished after the first few months of treatment, from 63% of
patients after 1 month to 8% after 6 months, but commented that
digestive adverse events were a barrier to compliance in their
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Level of
evidence
Design Treatment and
mean dose
Outcome Reference
Mean change in
serum uric acid vs
baseline at 52 weeks
Patients with
clinically significant
decrease in uric acid
concentrationa
% change in mean
serum uric acid vs
baseline at end of
treatment (12 weeks)
Mean serum uric acid
during each
treatment period
2 Open, RCT, 52
weeks, n=81 (S),
n=88 (Ca salts)b
Subanalysis of
Chertow et al.
2002
Sevelamer
6.5 g/day
Ca saltsc
S decrease
0.64 mg/dL
Ca salts decrease
0.26 mg/dL
(P=0.03 S vs Ca salts)
S 23%
Ca salts 10%
(P=0.02 S vs Ca salts)
NR NR Garg et al. 2005
2 Open, RCT, 52
weeks, n=36 (S),
n=46 (CaCO3)b
Sevelamer
5.9 g/day
CaCO3
3.9 g/day
S decrease 40 µmol/L
(P<0.0001 vs baseline)
CaCO3 NR
NR NR NR Braun et al.
2004
3 Open, 12
weeks, n=18
patients with
severe
secondary
hyperpara-
thyroidism
Sevelamer NR NR Decrease 9% (P<0.05
vs baseline)
NR Castro et al.
2002
3 Switching study
in 45 patients 
Standard
phosphate
binders for 6
months, then 1
month
cotreatment,
then S for 6
months
NR NR NR S 5.9 mg/dL
Standard binders
7 mg/dL
(P=0.0001, S period vs
standard period)
Sandberg et al.
2002
aDefined by the authors as a reduction of 1.5 mg/dL or more.
bPatients for whom both baseline and follow-up data were available.
cMean dose not given, but in the primary analysis (Chertow et al. 2002), the mean dose was 4.3 g/day.
Ca, calcium; CaCO3, calcium carbonate; NR, not reported; RCT, randomized controlled trial; S, sevelamer.
Table 8 | Effects of sevelamer on serum uric acid
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patients (Huu et al. 2002). In a group of 34 patients switched to
sevelamer for previously uncontrolled hyperphosphatemia,
gastrointestinal complaints were reported in 23 patients (67%)
(Almirall et al. 2004).
On balance, this suggests that sevelamer can be associated with
the occurrence of troublesome gastrointestinal adverse events,
but the evidence does not clearly show whether the incidence is
higher with sevelamer than with calcium salts. Some of the
earlier evidence of adverse gastrointestinal effects may have
resulted from the high pill counts associated with the earlier
sevelamer 403 mg formulation, rather than the 800.mg
formulation now in use. 
Bone mineral density
Limited evidence, from a subanalysis of patients in the Chertow et
al. (2002) study for whom data on bone mineral density [measured
by computed tomography densitometry and expressed in
Hounsfield Units (HU)] were available at baseline and after 52
weeks of treatment, indicates that patients treated with calcium
salts (n=68) experienced significant loss in trabecular bone mineral
density during treatment (median absolute change from baseline
–7.9 HU, P<0.05), while sevelamer-treated patients (n=57) showed
no loss of trabecular bone mineral density (median absolute change
from baseline 0, P=NS) (Raggi et al. 2003). The difference between
the two groups was statistically significant (P=0.01; Raggi et al.
2005). Further evidence is needed to confirm this finding and to
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Level of
evidence
Design Treatment and
mean dose
Outcome Reference
Serum bicarbonate % patients with
serum bicarbonate
<20 mmol/L
Mean serum pH
after 2 years
Mean partial pressure
CO2 after 2 years
1 Systematic review Sevelamer
Sevelamer plus
supplemental
Ca
Placebo
CaAc
CaCO3
NSD S vs placebo
(1 study)
NSD S vs CaCO3
(1 study)
NSD S vs S+Ca
(1 study)
Lower with S vs Ca
salts (P<0.0001)
(1 study)
NR NR NR Manns et al.
2004
2 Double-blind, RCT,
8 weeks, n=50 (S),
n=48 (CaAc)
Sevelamer
6.9 g/day
CaAc 7.1 g/day
Lower with S vs CaAc
(P<0.0001)
NR NR NR Qunibi et al.
2004
3 Retrospective, 2
years, n=17 (S),
n=7 (Ca or Al salts)
Sevelamer
Ca or Al salts
Decrease with S
(P=0.002)
NSD with Ca or Al
salts
NR NR NR Sonikian et al
2005
3 Retrospective,
n=583 (S), n=2923
(CaCO3), n=3664
(CaAc)
Sevelamer
CaCO3
CaAc
Lower with S vs Ca
salts (P<0.0001 S
period vs Ca salts
period)
S 46.9%
CaCO3 42.4%
CaAc 40.8%
NR NR Walters et al.
2002a
3 Retrospective,
n=30 (S), n=25 (Ca
salts)
Sevelamer
Ca salts
Lower with S vs Ca
salts (P<0.05)
S 77%
Ca salts 36%
(P<0.05 S vs Ca salts)
NR NR Ciampi & Reilly
2002
3 Switching study, 7
patients with high
Ca × P product
and severe
hyperpara-
thyroidism
switched to S, 7
control patients
with well-controlled
Ca × P and mild
hyperpara-
thyroidism
continued on
calcium salts
Sevelamer
Ca salts
NSD vs baseline for
S and Ca salts
NR S 7.37 (decline from
7.40 at baseline,
P<0.05)
Ca salts NSD vs
baseline
S 36 mmHg (decline
from 42.5 mmHg at
baseline, P<0.05)
Ca salts NSD vs
baseline
Vlahakos et al.
2004
Ca, calcium; CaAc, calcium acetate; CaCO3, calcium carbonate; NR, not reported; NSD, not statistically significantly different; RCT, randomized controlled trial; S, sevelamer.
Table 9 | Effects of sevelamer on measures of metabolic acidosis
                                        investigate the influence of sevelamer on other aspects of bone
morbidity (e.g. incidence of fractures and bone pain).
Cardiovascular morbidity and mortality
As arterial calcification is associated with increased mortality
(London et al. 2003), the reduction in arterial calcification observed
with sevelamer compared with calcium salts could have important
potential survival benefits. A modeling study (Huybrechts et al.
2005) has explored this area, using data on arterial calcification
obtained from an RCT (Chertow et al. 2002) combined with data on
cardiovascular risk from a cohort study. Multivariate regression
analysis of the data from Chertow et al. (2002) was used to
develop an equation to predict the arterial calcification score from
baseline clinical characteristics and medical history. This equation
was then applied to data from a cohort of 179 patients from a
single dialysis center in France, who were followed up for a mean
of 4 years. The calcification score for each of these patients was
estimated using the equation developed from the Chertow et al.
(2002) data, and this predicted score was then included in
regression analysis of cardiovascular risk. The predicted
calcification score was significantly associated (P<0.0001) with the
4-year cardiovascular risk, and an equation was developed to
estimate the cardiovascular risk from the calcification score
(Huybrechts et al. 2005). Applying this equation to the calcification
score data in the treatment groups from Chertow et al. (2002)
allowed the authors to estimate that in a population of 100
patients, treatment with sevelamer rather than calcium salts would
prevent a total of nine cardiovascular events over the patients’
lifetimes (Huybrechts et al. 2005). 
Further results from this modeling study have been presented in
abstract form (Caro et al. 2003). This estimated that in a cohort of
100 patients, sevelamer treatment for 1 year would prevent nine
future cardiovascular events and save 18 life-years compared with
calcium acetate treatment, and prevent 10 future cardiovascular
events and save 18 life-years compared with calcium carbonate
(Caro et al. 2003). 
A retrospective study in dialysis patients receiving sevelamer
(n=696), calcium acetate (n=4018), or calcium carbonate (n=3279)
during 2001 reported data on cardiac mortality (Walters et al.
2002b). Among the sevelamer patients, 10.8% died of cardiac
disease in 2001, compared with 16.6% of patients treated with
calcium acetate (P<0.001 vs sevelamer) and 12.6% of patients
receiving calcium carbonate (P=NS vs sevelamer). However, this
study was not randomized and the sevelamer group had a
significantly (P<0.001) lower mean age, a higher percentage of
women and a higher percentage of patients on peritoneal dialysis
compared with the other two groups (Walters et al. 2002b), which
may have affected the results. 
Sevelamer also sequesters bile acids and has been shown to
reduce serum lipid levels; this action may also have favorable
cardiovascular effects (Loghman-Adham 2003).
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Level of
evidence
Design Treatment and mean dose Outcome Reference
2 Open, 5 months, n=21 (S),
n=21 (CaCO3)
Sevelamer, initial dose 2.4 g/day
increasing to 4.4 g/day
CaCO3 4.8 g/day
Patients who discontinued due to digestive intolerance
S 5/21 
CaCO3 0
Sadek et al. 2003
2 Double-blind, 8 weeks, n=50
(S), n=48 (CaAc)
Sevelamer 6.9 g/day
CaAc 7.1 g/day
NSD S vs CaAc in subjective symptom score for
gastrointestinal side effects
Qunibi et al. 2004
2 Open, 34 weeks, n=40 total Sevelamer 4.09 g/day
CaAc 3.9 g/day
NSD S vs CaAc in occurrence of “constipation,
diarrhea and other adverse events”
Hervás et al. 2003
2 Open, 52 weeks, n=36 (S),
n=46 (CaCO3)a
Subanalysis of Chertow et al.
2002, German and Austrian
patients, with 11 additional
patients randomized
Sevelamer 5.9 g/day
CaCO3 3.9 g/day
Gastrointestinal adverse events:
S 74% 
CaCO3 53%
(P=0.02 S vs CaCO3)
Dyspepsia:
S 26%
CaCO3 5%
(P<0.01 S vs CaCO3)
Braun et al. 2004
2 Open, 52 weeks, n=108
randomized
Sevelamer 6.7 g/day
CaAc 4.6 g/day
NSD S vs CaAc in occurrence of gastrointestinal
adverse events
Chertow et al. 2003
3 Open, crossover, 8 weeks for
each treatment period, n=20
Sevelamer 5.2 g/day
CaCO3 9 g/day
Occurrence of gastrointestinal complaints:
S 28%
CaCO3 35%
Shaheen et al. 2004
aNumber who completed the trial.
CaAc, calcium acetate; CaCO3, calcium carbonate; NSD, no statistically significant difference; S, sevelamer.
Table 10 | Effects of sevelamer compared with calcium salts on occurrence of gastrointestinal adverse events
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Direct evidence from prospective RCT is required to fully assess the
effect of sevelamer on cardiovascular mortality and morbidity.
Hospitalization
A case–control study compared rates of hospitalization in sevelamer-
treated Medicare patients (n=152) enrolled in the study published by
Chertow et al. (1999b) and nonsevelamer-treated Medicare patients
(n=152) from the same dialysis facilities over the same time period,
matched for age, sex, race, diabetic status, and geographic location
(Collins et al. 2000). After adjusting for prior medical history and
severity of disease, Cox regression analysis showed a significant
reduction in the risk of hospitalization for any reason in the 17-month
study period in the sevelamer group (46–54% lower than in the control
group, P<0.03) (Collins et al. 2000). However, significantly more of the
control subjects had a history of cerebral vascular accidents or
transient ischemic attacks and gastrointestinal disease associated
with bleeding, compared with the sevelamer group. The sevelamer
patients were selected from a clinical study population with defined
inclusion/exclusion criteria, and the possibility that differences in the
patient population may have biased the results cannot be excluded,
as acknowledged by the authors (Collins et al. 2000). Evidence from
randomized trials is needed to assess this point.
Compliance
One observational study presented data on compliance with
phosphate binders (Tomasello et al. 2004). Interviews were
conducted with 188 dialysis patients (129 on hemodialysis), and
found that 37.8% of patients admitted noncompliance with their
phosphate binder (compliance defined as taking 80% of the tablets
prescribed). The noncompliant patients were prescribed higher
doses of phosphate binders than the compliant patients (9.3 vs 8.2
pills/day), but actually took smaller doses (4.2 vs 7.6 pills/day).
Noncompliant and compliant patients did not differ with respect to
the type of phosphate binder prescribed (categorized by the
authors into calcium binders vs noncalcium binders) (Tomasello et
al. 2004). This study did not provide specific evidence on rates of
compliance with sevelamer treatment. However, as the phosphate
binder medication burden with sevelamer is not notably different
from that with calcium salts (both require daily doses of several
grams), little difference would be expected, and the findings of
Tomasello et al. (2004) are consistent with this expectation.
Quality of life
No evidence was identified in the search on the effects of
sevelamer on health-related quality of life.
Other comparisons
A crossover study in six hemodialysis patients found that
colestimide, a bile-acid sequestrant with a similar chemical
structure to sevelamer, was significantly less effective than
sevelamer as a phosphate binder (Tajiri et al. 2004).
Combination treatment
Concern has been expressed over the cost of sevelamer compared
with calcium salts (McIntyre et al. 2002; Manns et al. 2004;
Sturtevant et al. 2004). It has been suggested that combination
treatment with low-dose sevelamer and low-dose calcium salts
could achieve effective phosphate control at a lower cost (Hergesell
& Ritz 2002). There has also been concern that Japanese patients
may be less tolerant of sevelamer treatment and more prone to
develop hypocalcemia because average dietary calcium intake is
lower in Japan than in Europe or the USA, leading to the suggestion
that combination treatment may be a useful alternative in this
population (Ogata et al. 2005). As the K/DOQI guidelines
recommend targets for various parameters without specifying how
these targets should be achieved, a number of investigators have
examined combination therapy as a possible means of achieving
K/DOQI targets. 
McIntyre et al. (2002) selected 23 hemodialysis patients with
hypercalcemia (serum calcium >2.6 mmol/L), and exchanged 50%
of their initial calcium binder dose for sevelamer. After 4 weeks, if
serum calcium was still above 2.6 mmol/L, a further 50% of the
calcium dose was replaced by sevelamer, and if serum calcium was
normal but serum phosphate was >2 mmol/L, the dose of
sevelamer was increased by 25%. Patients were then followed for
a further 4 weeks. Mean serum calcium declined significantly
during the study (from 2.8 to 2.56 mmol/L, P<0.0005), mean serum
phosphate showed no statistically significant change, and mean
intact PTH increased (from 166 to 276 ng/L, P=0.02). The
percentage of patients with hypercalcemia declined from 100 to
26%. The mean sevelamer dose was 2.77 g/day and the mean
calcium dose (measured as elemental calcium) was 1.03 g/day. The
authors concluded that combination treatment could achieve
control of serum phosphate without inducing hypercalcemia in the
majority of patients who had been hypercalcemic on their previous
phosphate binder treatment (McIntyre et al. 2002).
A further study replaced part of the calcium binder dose with
sevelamer in a group of 18 dialysis patients with serum phosphate
>1.8 mmol/L who were intolerant of other available phosphate
binders (Sturtevant et al. 2004). Sevelamer was added at an initial
dose of 403 mg three times daily and titrated to a maximum of
1209 mg three times daily. Mean serum phosphate and Ca × P
product were significantly (P=0.02) lower after addition of sevelamer
than before, with no significant change in serum calcium or PTH.
The mean dose of sevelamer was 2.4g/day and the mean dose of
elemental calcium decreased from 3.4g/day to 1.2g/day (P=0.04). 
A study in Japan treated a cohort of 210 patients with sevelamer
plus calcium carbonate, gradually increasing the sevelamer dose
and reducing the calcium carbonate dose over a period of 24
weeks (Shishido et al. 2004; Ogata et al. 2005). After 24 weeks, the
sevelamer dose was further increased to 3.29 g/day and the
calcium carbonate dose was decreased by 54%. Serum calcium
significantly decreased (P=0.0012), although there was also a small
increase in serum phosphate (from 5.89 mg/dL to 6.25 mg/dL,
P=0.017) (Ogata et al. 2005). Among patients with a baseline PTH
<150 pg/mL, PTH and phosphate increased and serum calcium
decreased compared with baseline (all P<0.05); while in those with
a baseline PTH 150–300 pg/mL, serum PTH increased without
statistically significant changes in calcium or phosphate; and in
those with a baseline PTH ≥300 pg/mL, there were no significant
changes in serum PTH, calcium, or phosphate. Vitamin D treatment
could be started or intensified in 23 of 66 patients with baseline
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                                  PTH ≥300 pg/mL, because of improved calcium and phosphate
control (Shishido et al. 2004). It is important to note that this study
utilized sevelamer to introduce or escalate vitamin D therapy in
order to avoid low calcium, which may have been the main
determinant of serum calcium and phosphate levels. The overall
doses of binder were low, which may explain the suboptimal
control of serum phosphate. 
Economic evidence
The major cause of death in patients with CKD is cardiovascular
disease (McCullough 2004; Foley et al. 2005). There is evidence
that sevelamer can reduce the rate of progression of arterial
calcification in hemodialysis patients compared with calcium salts,
perhaps due to the lower incidence of hypercalcemia with
sevelamer (Chertow et al. 2002), as discussed above in the Clinical
evidence section. Arterial calcification has been linked to
cardiovascular morbidity and mortality (London et al. 2003), and
thus a reduction would be expected to produce a corresponding
reduction in cardiovascular events and deaths. Such an
improvement in cardiovascular disease could potentially provide
substantial economic benefits, which in turn could offset the higher
acquisition price of sevelamer compared with calcium salts [in the
USA the mean annual cost of sevelamer was estimated at $US3644
per patient, compared with $US154 for calcium carbonate and
$US463 for calcium acetate (Manns et al. 2004)].
The economic effects of the reduction in arterial calcification with
sevelamer have been explored in a modeling study published in
abstract form (Caro et al. 2003). The model estimated
cardiovascular disease risk by combining calcification scores for
sevelamer and calcium salts, reported in an RCT (Chertow et al.
2002), with equations relating calcification score to cardiovascular
disease risk derived from a cohort study. In a cohort of 100
patients, the model estimated that 1 year of sevelamer treatment
would save 18 life-years and prevent nine future cardiovascular
events that would have cost $US205 600 to manage, resulting in a
net cost of $US37 900 for sevelamer compared with calcium
acetate (Caro et al. 2003). The corresponding values for sevelamer
compared with calcium carbonate were 18 life-years, 10
cardiovascular events prevented that would have cost $US226 700
to manage, and a net cost of $US19 500. The incremental cost-
effectiveness ratios for sevelamer compared with calcium acetate
were $US2200 per life-year gained and $US4400 per
cardiovascular event prevented; for sevelamer compared with
calcium carbonate the corresponding values were $US1100 per
life-year gained and $US2300 per cardiovascular event prevented
(Caro et al. 2003). The authors comment that these results show
that sevelamer is highly cost-effective, as the median cost-
effectiveness of dialysis is $US46 000 per life-year gained (Caro et
al. 2003). However, there has been debate over the cost-
effectiveness of sevelamer (Quinibi & Nolan 2005), and direct
evidence of the economic effects of sevelamer is required to
confirm these estimates.
A case–control study reported that average total Medicare
expenditure during the 17-month study was lower in patients
receiving sevelamer than in matched controls not receiving
sevelamer ($US4422 vs $US5866 per patient per month) (Collins et
al. 2000). However, there were baseline differences in the medical
history of the two groups that may have affected the results, and
these findings need to be replicated in randomized trials.
As discussed above in the Disease overview section, it has been
suggested that dyslipidemia may be a major determinant of
cardiovascular mortality in dialysis patients. A decision-analysis
model estimated the costs and cost-effectiveness of sevelamer
compared with calcium carbonate plus atorvastatin for reducing
LDL cholesterol in patients with CKD (Brophy et al. 2000). The
authors state that the modeled population represents patients with
CKD, hyperphosphatemia, and dyslipidemia who are not yet on
dialysis (Brophy et al. 2000). However, the sevelamer data used to
populate the model were derived from seven published sevelamer
trials, six of which were conducted in hemodialysis patients (the
other was in healthy volunteers), so the study is relevant to a review
of sevelamer in hemodialysis patients. The study estimated that the
total annual cost of treatment with calcium carbonate (1 g three
times per day) plus atorvastatin (10 mg/day) was $US1029 per
patient, while the cost of treatment with sevelamer (2 × 403 mg
capsules three times per day) was $US1579 per patient. The
estimated percentage of patients achieving a 35% reduction in LDL
cholesterol concentration was 74.2% in the calcium
carbonate+atorvastatin group, and 50.2% in the sevelamer group.
These results indicate that calcium carbonate+atorvastatin was both
more effective and less costly than sevelamer for reducing LDL
cholesterol in predialysis patients (Brophy et al. 2000).
However, the study has a number of serious limitations. First,
although the modeled population is stated to be predialysis patients
with hyperphosphatemia and dyslipidemia, the sevelamer data were
derived from studies in healthy volunteers or hemodialysis patients,
whereas the data for the calcium carbonate+atorvastatin group were
derived from studies of atorvastatin alone in patients with
hypercholesterolemia and/or cardiovascular risk factors without
CKD. Thus, the efficacy data used to populate the model are derived
from different patient populations, neither of which is the modeled
population. Second, the sevelamer studies did not report data on
the percentage of patients who achieved a 35% reduction in LDL
cholesterol, so the authors assumed that the probability would be
50%. Third, the authors assumed that hypercalcemia was “generally
not of concern” and did not consider possible effects of
hypercalcemia on costs or effectiveness. Fourth, the model did not
take account of any costs associated with adverse events. Fifth, the
effectiveness data were derived from trials lasting 8–16 weeks
(atorvastatin) or 15 days–44 weeks (sevelamer), and these data may
not be capable of extrapolation to the modeled period of 1 year.
Sixth, the choice of effectiveness measure (reduction in LDL
cholesterol by 35%) relies on an assumption that this is a key
determinant of cardiovascular risk in CKD patients and does not
take account of other potential cardiovascular risk factors in these
patients, such as arterial calcification score, elevated serum
calcium, and/or Ca × P product. It is not unexpected that
atorvastatin, designed and used specifically as a lipid-lowering
agent, should prove to be more effective at lipid-lowering than
sevelamer, which was designed and used as a phosphate binder.
These limitations, most of which are acknowledged by the study
authors, limit the potential applicability of the model’s findings. 
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Some evidence indicates that sevelamer may be associated with
better preservation of trabecular bone mineral density than calcium
salts (Raggi et al. 2003). This may have the potential to save costs
associated with the management of bone disease (e.g. costs of
managing fractures or treating bone pain). However, direct
evidence is required on this issue.
Further economic studies on a range of outcomes are required to
evaluate the cost-effectiveness of sevelamer as a phosphate binder
in hemodialysis patients.
Resource utilization
The acquisition price of sevelamer is substantially higher than that
of calcium salts. The potential budget impact of using sevelamer in
all patients who meet the K/DOQI guideline criteria for its use (see
Patient population section below) has been estimated for the USA
and Canada (Manns et al. 2004). In Canada, 51% of a cohort of
dialysis patients (407 hemodialysis, 92 peritoneal dialysis) met the
K/DOQI criteria for use of sevelamer. Extrapolating this figure to the
total Canadian dialysis population, the authors estimated that using
sevelamer in all patients meeting the K/DOQI criteria would result in
an expenditure of $US26 million per year on sevelamer. Of a cohort
of 1600 hemodialysis patients and 400 peritoneal dialysis patients
in the USA, 64% met the K/DOQI criteria for sevelamer use, and
extrapolating this to the total US dialysis population projected that
$US781 million per year would be spent on the drug (Manns et al.
2004). The authors estimated that hospitalization costs for ESRD
patients would have to be reduced by 45% in Canada and by
considerably more (detailed estimate not provided) in the USA to
offset the additional cost of sevelamer (Manns et al. 2004).
It has been suggested that using a combination of sevelamer and a
low dose of calcium salts may be effective in controlling serum
phosphate and result in a lower cost than with sevelamer alone
(Hergesell & Ritz 2002), but there is little evidence on this point at
present.
Sevelamer has been shown to attenuate the progression of arterial
calcification compared with calcium salts, which has the potential
to reduce the excess cardiovascular morbidity and/or mortality
seen in hemodialysis patients. A modeling study has estimated that
sevelamer treatment could reduce the costs of managing
cardiovascular events in a cohort of 100 patients by $US205 600
compared with calcium acetate and $US226 700 compared with
calcium carbonate (Caro et al. 2003). These savings offset most of
the additional acquisition cost of sevelamer, resulting in net costs
for the cohort of $US37 900 compared with calcium acetate and
$US19 500 compared with calcium carbonate (Caro et al. 2003).
Direct evidence is required to confirm these potential savings in
cardiovascular treatment costs.
A case–control study has estimated that the risk of hospitalization
over the 17-month study period was 46–54% lower in US Medicare
patients treated with sevelamer compared with matched controls
receiving other phosphate binders (Collins et al. 2001), and this
could indicate substantial potential savings in direct treatment costs
for patients receiving sevelamer. However, as previously discussed,
this study reported significant baseline differences in medical history
between the two groups, which may have influenced its results.
Prevention of cardiovascular morbidity should also reduce indirect
costs (e.g. more patients may be able to work and/or undertake
normal activities) and provide intangible benefits (e.g. improved
quality of life), but the search identified no direct evidence relating
to these potential economic benefits.
There is, at the time of writing, insufficient evidence to estimate
the overall effect of sevelamer on resource utilization. Some
evidence from retrospective and modeling studies suggests that
higher expenditure in the drug budget (which follows from the
higher acquisition cost of sevelamer compared with calcium salts)
could be offset by savings elsewhere or justified by additional
health benefits, but this needs to be confirmed by direct evidence
from prospective controlled studies designed to measure
economic endpoints.
Patient group/population
Sevelamer is indicated for the treatment of adult patients on
hemodialysis. While it may have potential benefits for other groups,
such as children, patients on peritoneal dialysis, or predialysis
patients, such off-label use is outside the scope of this review.
The NKF K/DOQI guidelines recommend sevelamer as a phosphate
binder in the following clinical situations:
• In dialysis patients who remain hyperphosphatemic (serum
phosphate >5.5 mg/dL) despite the use of calcium-based binders
or other noncalcium-, nonaluminum-, nonmagnesium-containing
binders, a combination should be used
•  In dialysis patients, the total dose of elemental calcium from
calcium-based phosphate binders should not exceed
1500 mg/day. For comparison, the recommended daily dose of
calcium acetate (3–4 capsules three times per day) equates to
1521–2028 mg/day elemental calcium (PhosLo® US package
insert http://www.fda.gov/cder/foi/label/2001/21160lbl.pdf)
• In dialysis patients, calcium-based binders should not be used in
patients with hypercalcemia (serum calcium >10.2 mg/dL) or with
serum PTH <150pg/mL
• In dialysis patients with severe soft-tissue calcifications,
noncalcium-based phosphate binders are preferred
• Adynamic bone disease should be treated by increasing PTH to
≥100 pg/mL by decreasing or eliminating calcium-based
phosphate binders.
It has been estimated that 64% of US and 51% of Canadian
dialysis patients would meet the K/DOQI criteria for the use of
sevelamer (Manns et al. 2004).
Patients with uncontrolled hyperphosphatemia
A study in 34 patients with uncontrolled hyperphosphatemia (serum
phosphate >6.5 mg/dL and/or toxicity or intolerance to calcium- or
aluminum-based phosphate binders) found that the addition of
sevelamer provided better control of serum phosphate and Ca × P
product and allowed a reduction in the dose of other binders
(Almirall et al. 2004). However, 13 of 34 patients (38%) dropped out
because of intolerance to sevelamer, mainly (no number or
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              percentage specified) due to gastrointestinal adverse effects
(Almirall et al. 2004). In a crossover study of 10 patients with
uncontrolled hyperphosphatemia (serum phosphate
6.6–10.4mg/dL), the effect of sevelamer on serum phosphate was
similar to that of standard phosphate binders (Apostolou et al.
2002). A study in 18 patients with hyperphosphatemia [serum
phosphate >1.8 mmol/L (>5.6 mg/dL)] who were intolerant of other
currently available phosphate binders found that combination
treatment with sevelamer and calcium carbonate reduced serum
phosphate and Ca × P product significantly (P=0.02) more than
calcium carbonate alone (Sturtevant et al. 2004).
Patients with severe secondary hyperparathyroidism
In 18 patients with severe secondary hyperparathyroidism (mean
serum intact PTH concentration 810 pg/mL), switching to
sevelamer produced significant (P<0.05) reductions in serum
phosphate and serum calcium, with no change in PTH, leading the
authors to conclude that sevelamer is an effective phosphate
binder in such patients (Castro et al. 2002). A further study, in which
sevelamer replaced aluminum hydroxide in 11 hemodialysis
patients with secondary hyperparathyroidism, reported that
sevelamer significantly reduced mean serum phosphate and mean
serum intact PTH after 8 weeks (both P<0.003), but that there was
no statistically significant change in mean serum calcium
(Mitsopoulos et al. 2002b).
Patients taking concurrent vitamin D and/or calcium
supplements
A subgroup analysis of a cohort of patients who received sevelamer
for 1 year (Chertow et al. 1999b) found that sevelamer significantly
reduced serum phosphate and Ca × P regardless of whether
patients were also taking vitamin D, calcium supplements, or both
(Chertow et al. 2000).
Japanese patients
It has been suggested that Japanese patients may be less tolerant
of sevelamer treatment and more prone to develop hypocalcemia
because average dietary calcium intake is lower in Japan than in
Europe or the USA (Ogata et al. 2005). A cohort study in 210
hemodialysis patients in Japan concluded that a combination of
sevelamer and calcium carbonate could reduce calcium load
compared with calcium carbonate alone, while still avoiding the
development of hypocalcemia (Ogata et al. 2005).
Dosage, administration, and formulations
Sevelamer (Renagel®) is indicated for the control of
hyperphosphatemia in adult patients on hemodialysis. It is available
as film-coated tablets each containing sevelamer 800 mg.
For patients who are not taking phosphate binders and whose
serum phosphate concentration is 1.94–2.42 mmol/L, the
recommended starting dose is 1 × 800 mg tablet three times daily,
increasing to 2 × 800 mg tablets three times daily if the serum
phosphate concentration is >2.42 mmol/L. In patients who are
being switched from alternative phosphate binders, the starting
dose of sevelamer should be the milligram equivalent of the
patient’s previous dose of calcium-based phosphate binder. Serum
phosphate concentrations should be measured every 2–3 weeks,
and the dose of sevelamer titrated with the goal of reaching a
serum phosphate concentration of 1.94 mmol/L or less. The dose
range may vary between 1 and 5 × 800 mg tablets three times daily.
Sevelamer should be taken with meals (Anon. 2004).
Place in therapy
The evidence summary table at the beginning of the article
summarizes the clinical evidence for the impact of sevelamer on
clinical and economic outcome measures. The strongest evidence
was found for disease-oriented outcomes, such as arterial
calcification score and reduction of serum phosphate, calcium and
lipid concentrations. Although these may be markers of beneficial
effects on patient-oriented outcomes (e.g. arterial calcification may
be linked to a reduction in cardiovascular morbidity and mortality),
in themselves they do not demonstrate improved length or quality
of life. The evidence on patient-oriented outcomes was less clear.
There was an indication of reduced cardiovascular mortality and
morbidity, but the evidence on this outcome is derived from a
modeling study and requires confirmation by direct observation.
Among other patient-oriented outcomes, sevelamer may reduce
hospitalization risk but this is derived from a case–control study
and requires confirmation by randomized trials. Limited evidence
from case reports and a small observational study suggests that
reduction of Ca × P product by treatment interventions including
sevelamer may improve healing of ulcers associated with calcific
uremic arteriolopathy. This is of clear potential benefit to patients
with this uncommon but serious and distressing condition, but it
should be noted that there is no evidence comparing sevelamer
with other noncalcium binders.
There is strong evidence that sevelamer is as effective as calcium
salts in lowering serum phosphate and serum Ca × P product, with
only one study finding to the contrary. Similarly, there is strong
evidence that sevelamer is associated with a lower incidence of
hypercalcemia than calcium salts. Only one study failed to show a
statistically significant difference in hypercalcemia incidence in
favor of sevelamer, and this study was not powered to detect a
difference (Hervás et al. 2003). There is also strong evidence that
sevelamer reduces LDL cholesterol more than calcium salts, with
no results to the contrary.
Some evidence indicates that sevelamer reduces serum
bicarbonate concentration more than calcium salts. Two studies
have reported no statistically significant difference, but neither
was powered on this endpoint. Data from a small single-group
study, reported in abstract form, indicates that respiratory
compensation (reduction in partial pressure of CO2) maintains
serum pH in the normal range.
Evidence from one RCT (and several subanalyses) from the Treat to
Goal Working Group study shows that sevelamer reduces the
progression of arterial calcification compared with calcium salts.
There is limited evidence that may indicate a beneficial effect of
sevelamer as part of a therapeutic regimen for the management of
calcific uremic arteriolopathy, with improvement and/or healing of
ulcerations reported in a small observational study and two case
reports. Some evidence also indicates that sevelamer reduces serum
uric acid concentrations to a greater degree than calcium salts.
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The attenuation of arterial calcification is potentially of great
therapeutic value, as this has been suggested as a possible
mechanism underlying the excess cardiovascular morbidity and
mortality in CKD patients. A modeling study has estimated that the
reduction in arterial calcification associated with sevelamer
treatment could prevent 9–10 future cardiovascular events and
save 18 life-years in a cohort of 100 patients. A retrospective study
has also observed lower cardiac mortality in sevelamer-treated
patients than in those receiving calcium acetate, although the study
was not randomized and there were baseline differences between
the groups that could have affected the results. Similarly, sevelamer
was associated with a lower risk of hospitalization than calcium
salts in a case–control study, but this study could also have been
biased by significant differences between the groups at baseline.
A subanalysis of data from one RCT showed that sevelamer
could preserve trabecular bone mineral density compared with
calcium salts. This may suggest a beneficial effect on bone
morbidity, but direct evidence is needed to confirm this
possibility.
The evidence is divided with regard to the incidence of
gastrointestinal adverse events, with six studies providing some
comparison between sevelamer and calcium salts, two of which
found that sevelamer was associated with a higher frequency of
gastrointestinal adverse events than calcium salts while four
reported no statistically significant difference. However, the
evidence is limited in its applicability, since there was no consistent
definition of gastrointestinal adverse events across the studies and
so it is difficult to draw a firm conclusion about where the balance
lies. Moreover, all but one of the studies were open label, a design
known to be subject to potential bias in the reporting of subjective
events. It may be significant that the one double-blind comparative
study (Qunibi et al. 2004) reported no statistically significant
difference between sevelamer and calcium acetate in subjective
symptom scores for gastrointestinal adverse events, although the
study was not powered to detect a difference. Further evidence on
this point is required. No evidence was identified in this review on
the effect of sevelamer on quality of life. 
Limited evidence from one study suggested that the phosphate
binder medication burden and patient adherence to therapy was no
different with sevelamer than with calcium salts. Although this
evidence is weak in itself, it is consistent with the fact that average
doses of sevelamer are several grams per day, which is not
dissimilar to the doses of calcium salts. No marked improvement in
phosphate binder medication burden would thus be expected.
Considering economic evidence, it is clear that the acquisition cost
of sevelamer is higher than that of calcium salts. However, a
modeling study estimated that this increased acquisition cost could
be largely offset by reduced cardiovascular mortality and morbidity,
and estimated the incremental cost-effectiveness ratio for
sevelamer compared with calcium salts at $US1100–2200 per life-
year gained. However, direct evidence is needed to confirm these
estimates before the true economic benefits and cost-effectiveness
of sevelamer can be assessed.
In summary, there is strong evidence that sevelamer is as effective
as calcium salts in controlling serum phosphate and Ca × P
product, has less risk of inducing hypercalcemia, and is more
effective at lowering lipid levels. Some evidence also indicates that
sevelamer is more effective than calcium salts in reducing the
progression of arterial calcification, which may in turn be
associated with reduced cardiovascular mortality and/or morbidity.
It has been estimated that savings in treatment costs associated
with cardiovascular events could offset most of the additional
acquisition cost of sevelamer compared with calcium salts.
However, direct evidence is required to confirm the effects of
sevelamer on cardiovascular morbidity and mortality and to assess
its cost-effectiveness.
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